NCT03219671View on ClinicalTrials.gov

Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)

PHASE2UnknownINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

September 1, 2020

Study Completion Date

September 1, 2022

Conditions

Classic Kaposi Sarcoma

Interventions

DRUG

Nivolumab

nivolumab 240mg every 2 weeks

DRUG

Ipilimumab

ipilimumab 1 mg/kg every 6 weeks

Trial Locations (1)

Unknown

RECRUITING

Rabin Medical Center, Petah Tikva

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Alona Zer

OTHER

NCT03219671 - Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) | Biotech Hunter | Biotech Hunter